Evidence map›Paper›PMID 41338596›Full record

ArticleBMJ open respiratory research2025

Current practices, perceptions and future challenges in the management of moderate to severe COPD: a cross-sectional survey of respiratory consultants in the Republic of Ireland.

Jayleigh Lim, Helen O'Brien, Jack McCarthy, Cormac McCarthy, Alessandro Naoise Franciosi

Abstract read
In one paragraph

Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jayleigh LimDepartment of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
Helen O'BrienDepartment of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
Jack McCarthyDepartment of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
Cormac McCarthyDepartment of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.ORCID http://orcid.org/0000-0003-2896-5210
Alessandro Naoise FranciosiDepartment of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland alessandro.franciosi@ucd.ie.ORCID http://orcid.org/0000-0002-4241-8718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvidence is growing for interventions beyond inhaled therapies in chronic obstructive pulmonary disease (COPD). Clinician attitudes and access to these therapies are crucial to informing COPD care pathways.

aimsWe sought to explore current attitudes, practices, future directions and challenges in the management of moderate to severe COPD among respiratory consultants in the Republic of Ireland (ROI).

methodsA custom online survey was disseminated by email and text messaging to respiratory consultants in the ROI through the Irish Thoracic Society contact list.

results37 responses were received (24.5% response rate), of which 36 were eligible for inclusion. Completion rate was 97.2% (n=35). Only 9 of 30 respondents (30%) reported sufficient access to pulmonary rehabilitation (PR), and 9 of 29 (31%) to a dedicated COPD multidisciplinary team (MDT). 10 of 29 respondents (34%) infrequently or never consider long-term non-invasive ventilation (LTNIV), despite 21 of 27 (78%) rating the quality of evidence for its benefit in reducing hospitalisations as moderate or high. 16 of 27 respondents (59%) infrequently or never consider lung volume reduction (LVR), despite 22 of 25 (88%) perceiving it to be moderately or highly beneficial towards improving quality of life. There was variable uncertainty regarding the evidence for biologics in COPD, with up to 11 of 24 respondents (46%) uncertain about Tezepelumab. Perceived challenges to integrating biologics into COPD care in the ROI included the absence of national drug reimbursement agreements, lack of dedicated COPD MDTs and administrative burden.

conclusionsOur study highlights insufficient access to PR and COPD MDTs, variable attitudes towards LTNIV and LVR, and uncertainty around the role of biologics in COPD care. While the modest response rate may limit generalisability, our findings underscore the need to address infrastructural and systemic barriers to optimise care pathways for moderate to severe COPD in the ROI.

Indexed as

Attitude of Health PersonnelHealth PersonnelPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveRespiratory TherapyCross-Sectional StudiesDisease ManagementHealth Care SurveysHumansIrelandPatient Care TeamSocieties, MedicalThoracic SurgeryCOPD PharmacologyNon invasive ventilationPulmonary Disease, Chronic ObstructivePulmonary Rehabilitation

Identifiers

PMID41338596
PMCPMC12673536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.